Futura Medical (GB:FUM) has released an update.
Futura Medical PLC has successfully launched its flagship sexual health product, Eroxon®, in at least ten countries, including key European markets, with revenues aligning with market expectations for FY2024. The company is optimistic about further launches planned for the second half of the year and projects profitability within the next 12 months. In partnership with global consumer healthcare company Haleon, Futura is also preparing for the US market entry of Eroxon®, anticipated within the year.
For further insights into GB:FUM stock, check out TipRanks’ Stock Analysis page.
